Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
January 08 2024 - 8:20AM
Vector Pharma FZCO (Vector) today announced that it has entered
into an exclusive distribution agreement with Danish company
Ascendis Pharma A/S (Nasdaq: ASND) to commercialize both Skytrofa™
and Yorvipath™ in the Gulf Cooperation Council (GCC) countries of
Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and
Bahrain.
Under the terms of this exclusive distribution agreement, Vector
will employ its sales and marketing expertise to distribute both
Skytrofa and Yorvipath to patients in the GCC countries for the
treatment of pediatric growth hormone deficiency (GHD) in the case
of Skytrofa, and adult hypoparathyroidism in the case of
Yorvipath.
“I am excited to announce this regional agreement with Ascendis
Pharma,” commented Vector Pharma FZCO Managing Partner, Patrick
Jordan. “In Skytrofa, we have the opportunity for patients in our
region to have access to an FDA- and European Commission-approved
once-weekly treatment for children and adolescents with GHD, and
Yorvipath as a European Commission-approved parathyroid hormone
replacement therapy for adults with chronic hypoparathyroidism.
Introducing TransCon technology-based therapeutics to the GCC will
provide important tools for Endocrinologists and other Health Care
Providers seeing these disorders.”
“We are pleased to partner with Vector Pharma, a company with a
demonstrated ability to work effectively with patients, payers, and
providers in GCC countries,” said Camilla Harder Hartvig, Ascendis
Pharma’s Executive Vice President and Chief Commercial Officer.
“Their deep experience in the region will support our shared goal
of bringing to market new treatment options designed to address the
needs of patients living with these rare diseases.”
About Vector Pharma FZCO
Vector Pharma was founded in 2019 with the ambition to be the
leading full service distributor for rare diseases, oncology and
highly specialized therapeutics in the Middle East, North Africa,
and Turkish markets. As the only TRACE certified full service
distributor in the region, Vector has an equal emphasis on patient
demand generation through evidence-based medicine, fast track
market access solutions, and highest compliance & ethical
standards, all the while striving for the best outcomes for
patients, prescribers, and partners.
Vector Pharma is also a proud founding member of the World
Orphan Drug Alliance (WODA) offering its services together with
like-minded sister companies in Switzerland, CEE, Russia & CIS,
Israel, Greece/Cyprus/Malta, Africa, Greater China, SE Asia &
ANZ and Latin America.
More information can be found at www.vectorpharma.me or at
custops@vectorpharma.me.
About Ascendis Pharma
Ascendis Pharma is applying its innovative platform
technology to build a leading, fully integrated biopharma company
focused on making a meaningful difference in patients’ lives.
Guided by its core values of patients, science and passion, the
company uses its TransCon technology platform to create new and
potentially best-in-class therapies. Please visit
https://ascendispharma.com to learn more.
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Oct 2023 to Oct 2024